Har­vard prof David Sin­clair backs an­ti-ag­ing up­start Life Bio, which just raised $50M for re­search

You can add Life Bio­sciences to the list of biotech star­tups look­ing to make a name for them­selves in the bur­geon­ing field of an­ti-ag­ing drug re­search.

The Boston-based biotech — which has close ties to David Sin­clair, a Har­vard ge­neti­cist who’s been in­volved in a va­ri­ety of star­tups — says to­day that it’s lined up $50 mil­lion in B round cash. There’s no word on who ex­act­ly is in­vest­ing in the com­pa­ny, but there’s no short­age of am­bi­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER